Evidence map›Paper›PMID 38422508›Full record

ArticleThe Journal of organic chemistry2024

Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery Program.

Athenea N Aloiau, Briana M Bobek, Kersti Caddell Haatveit, Kelly E Pearson, Ashlee H Watkins, Benjamin Jones, Christopher R Smith, John M Ketcham, Matthew A Marx, Stephen J Harwood

Abstract read
In one paragraph

Article in The Journal of organic chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Athenea N AloiauMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Briana M BobekMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Kersti Caddell HaatveitMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Kelly E PearsonMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Ashlee H WatkinsMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Benjamin JonesMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
Christopher R SmithMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
John M KetchamMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.ORCID 0000-0001-5011-9593
Matthew A MarxMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.ORCID 0000-0003-2351-4787
Stephen J HarwoodMirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.ORCID 0000-0003-2127-7239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chiral amine synthesis remains a significant challenge in accelerating the design cycle of drug discovery programs. A zirconium hydride, due to its high oxophilicity and lower reactivity, gave highly chemo- and stereoselective reductions of sulfinyl ketimines. The development of this zirconocene-mediated reduction helped to accelerate our drug discovery efforts and is applicable to several motifs commonly used in medicinal chemistry. Computational investigation supported a cyclic half-chair transition state to rationalize the high selectivity in benzyl systems.

Indexed as

Organometallic CompoundsZirconiumAminesChemistry, PharmaceuticalAminesOrganometallic CompoundsZirconiumZirconocene dichloride

Identifiers

PMID38422508
PMCPMC10949245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.